KaloBios (KBIO) Crumbles: Shkreli Arrested & Fired, Delisted And Board Members Quit – ValueWalk Premium
KaloBios Pharmctcls (KBIO)

KaloBios (KBIO) Crumbles: Shkreli Arrested & Fired, Delisted And Board Members Quit

KaloBios, the relatively unknown penny stock pharma company, which was on the verge of bankruptcy, hit the headlines after controversial figure Martin Shkreli took a large stake in the company and became its CEO, is falling apart as managers flee the sinking ship.

Prior to Shkreli's investment, at the beginning of December, KaloBios was running out of cash fast and had planned to shut down before the end of the year. However, Shkreli rode to the rescue of KaloBios with a $8.2 million . . .


This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click chat.

Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers